Why is Valneva stock rallying today?

Valneva's stock surged 5.8% to €2.648 following the release of positive results from two Phase 2 trials of its tetravalent Shigella vaccine candidate, S4V2. The French specialty vaccine company demonstrated a favorable safety profile in an infant immunogenicity and safety trial conducted in Kenya, with mostly mild to moderate adverse events and significant antibody increases against all four targeted Shigella serotypes six months after vaccination.

Additionally, a controlled human infection model trial in U.S. clinical sites met its primary endpoint by showing a statistically significant reduction in shigellosis incidence among vaccinated participants compared to placebo. With no licensed competitor for S4V2, the company's data release provides a compelling reason for investors to re-rate the program, making today's rally purely company-driven and independent of any supportive macro or sector-wide momentum.